An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib as monotherapy and in combination in patients with advanced solid/metastatic tumours.
An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib as monotherapy and in combination in patients with advanced solid/metastatic tumours.